MedPath

Hotspot Therapeutics, Inc.

Hotspot Therapeutics, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2017-01-01
Employees
51
Market Cap
-
Website
http://www.hotspotthera.com

Clinical Trials

3

Active:2
Completed:1

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
phase_1_2
1 (33.3%)

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Phase 1
Active, not recruiting
Conditions
Solid Tumor, Adult
Refractory Cancer
Relapsed Cancer
Interventions
First Posted Date
2022-12-22
Last Posted Date
2025-02-04
Lead Sponsor
HotSpot Therapeutics, Inc
Target Recruit Count
77
Registration Number
NCT05662397
Locations
🇺🇸

Florida Cancer Specialists, Sarasota, Florida, United States

🇺🇸

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States

🇺🇸

Montefiore Einstein Comprehensive Cancer Center, Bronx, New York, United States

and more 11 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.